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We performed positron emission tomographic (YET) measurements of the regional distribution volume of benzodiaze- 
pine receptors and regional glucose metabolism in 6 drug-free patients with early Huntington’s disease following 
injection of EL1C}tlumazenil, a nonsubtype selective central benzodiazepine receptor antagonist. and “F-2-fluoro-2- 
deoxy-n-glucose, respectively. Flumazenil data were analyzed with a recently developed two-compartment, two- 
parameter tracer kinetic model. Benzodiazepine receptor density is related to distribution volume for flumazenil. In 
comparison with a group of healthy volunteers, benzodiazepine receptor density was significantly decreased in the 
caudate nucleus. Glucose metabolism was significantly reduced not only in the caudate nucleus but also in the putamen 
and thalamus. The changes in benzodiazepine receptor density observed in the caudate nucleus are commensurate 
with data obtained in postmortem autoradiographic studies of receptor density. Based on such postmortem studies we 
also anticipated changes in putamen and thalamic benzodiazepine receptor density. However, relatively little is known 
on receptor changes in early Huntington’s disease, because the autoradiographic data available were obtained mostly 
in patients with advanced disease. The decreased glucose metabolism in the caudate and putamen agrees well with 
previously published results of PET studies, whereas metabolic impairment of the thalamus has not yet been described 
in Huntington’s disease. The present study suggests that regional metabolism and y-aminobutyric acid (GABA)- 
benzodiazepine receptor changm in subcortical structures of patients with early Huntington’s disease do not occur 
with the same time course: Caudate benwdiazepine receptor density is already severely impaired when other subcorti- 
cal structures reveal only minor abnormalities. Impairment of neuronal metabolism seems to predate GAHAibenzodiaz- 
epine receptor changes since the putamen and thalamus demonstrate metabolic impairment without detectable loss 
of benzodiazepine receptor density. 
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Huntington’s disease (HI)) is an autosomal dominant 
inherited disorder characterized by the onset in midlife 
of progressive motor and cognitive dysfunction. Previ- 
ous studies with positron emission tomography (PET) 
and ~‘8F)-2-fluoro-2-deoxy-~-gl~cose (FDG) in pa- 
tients with symptomatic HI3 have shown marked de- 
clines in caudate and putamen glucose metabolism 
early in the disease arid possibly even presyrnptomati- 
c d y  Ll-6). The decline in caudate and putatnen FDG 
uptake correlated with the decline in functional capac- 
ity of the HD patients. Over 90% of caudate and puta- 
men neurons use y-aminobutyric acid (GABA) as a 
neurotransmitter [?) and these neurons send projec- 
tions to the lateral and medial globus pallidus and the 
substantia nigra pars reticulata. Postmortem biochemi- 
cal studies have revealed large decreases in GABA 
concentrations and glutamate decarboxylase (GAD; 
the enzyme that synthesizes GABA) activity in HD 
caudate and putamen as well as their projection zones 
[S, 91. In other postmortem studies of IID, binding 
sites for both GABA and benzodiazepines have been 
found to be decreased in striatum and increased in 
substantia nigra {9- 14}. Postmortem autoradiographic 
studies of GABA receptors labeled with competitive 
GABA agonists and benzodiazepine agonists (that bind 
to a modulatory site o n  the GABA receptor) have 
shown decreased binding in caudate and putamen and 
increased binding in globus pallidus El 5-18). This lat- 
ter increase presumably reflects a rompensatory upreg- 
ulation of pallidal receptors in response to denervation. 
In the superficial layer of the midfrontal cortex, total 
benzodiazepine receptor (BZR) binding was increased 
but its enhancement by GABA and barbiturates was 
significantly reduced {I 7) .  We have now utilized the 
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benzodiazepine antagonist ["C]flumazenil (FMZ) to 
examine BZRs by PET in living HD patients, and com- 
pared the  relative sensitivity of the  method t o  measure- 
ments  of glucose metabolism in the  same subjects. 
Materials and Methods 
Subjects 
Six patients (mean age, 5 3  I 9 years; 3 men, 3 women) with 
adult-onset HD underwent neurological examination and 
evaluation of total functional capacity (TFC) according to the 
Shoulson and Fahn scale [ 191 prior to the PET studies. The 
diagnosis of HD was made on the basis of the family history, 
physical examination, laboratory tests to exclude other dis- 
eases, and the findings on computer tomographic (CT) or 
magnetic resonance imaging (MRI) scans. All patients studied 
here exhibited little or no cerebral atrophy as measured by 
cranial CT or MKI. TFC assesses the patient's ability to be 
gainfully employcd, to handle financial affairs, to manage do- 
mestic responsibilities, to perform activities of daily life, and 
to be cared for at home. The TFC scale ranges from 13 to 
0, with 13 being normal and 0 indicating total incapacitation. 
Patients were in stage I (n = 3) or stage I1 (n = 3 ) ,  with a 
TFC for the group of 10.7 ? 1.6 (mean i standard devia- 
tion). The estimated duration of symptoms was approxi- 
mately 3 years in the stage I patients and 6 years in the 
stage I1 patients. They were compared with 6 normal control 
subjects (mean age, 50 ? 1 3  years) for the receptor studies 
and with 17 normal control subjects (mean age, 52 * 10 
years) for glucose metabolism studies. Control subjects were 
free of significant general medical, neurological, and psychiat- 
ric illness and had no family history of first-degree relatives 
with familial neurologic or psychiatric disease. They were 
also screened to exclude history of head trauma with loss of 
consciousness, drug or alcohol abuse, or dependence and 
excessive consumption of caffeine. They were free of pre- 
scribed sedatives, tranquilizers, and anxiolytics for 12 months 
prior to participation. The studies were approved by the Uni- 
versity of Michigan Institutional Review Boards and written 
informed consent was obtained for all studies. 
PGSitYGn Emijsion Tomagrapby lmagirzg 
A radial artery and cutaneous vein were cannulated for with- 
drawal of blood samples and for injection of the radioiso- 
topes, respectively. The subjects were positioned with their 
eyes and ears unoccluded in the gantry of a CTIiSiemens 
93 l/08- 12 tomograph (Siemens Gammasonics, Inc, Hoff- 
man Estates, IL). The scanner simultaneously acquires 15 
contiguous transaxial slices covering approximately a 10-cm 
axial field of view, with an inplane spatial resolution of ap- 
proximately 7- to 8-mm full width at half maximum. 
The 6 patients were first studied following injection of 
22.5 mCi ["C]FMZ and then underwent a second PET study 
following injection of 10 mCi FDG. The radioisotope injec- 
tions were separated by 100 minutes to allow decay and 
washout of residual isotope. Six age-matched control subjects 
underwent a single study following injection of 22.5 mCi 
{"C)FLVZ. Another 17 age-matched control subjects were 
examined with FDG only. 
A dynamic series of PET data (15 frames) and 30 to 35 
arterial blood samples were obtained over 60 minutes for 
the FMZ studies. Local cerebral metabolic rates for glucose 
(LCMRG) were calculated using a three-compartment model 
and a single-scan approximation with gray matter kinetic con- 
stants derived from normal subjects and a lumped constant 
of 0 5 4  A calculated attenuation correction was applied to 
all image reconstructions 
Correction of the Arterial Input Function for 
Flumazenil 
The time-course of ["CIFMZ following injection was deter- 
mined in arterial plasma with the use of an Nal  (En'hance, 
New England Nuclear, Boston, MA) well counter. Thirteen 
samples for each study were processed by liquid chromatog- 
raphy using Sep-Pak C,, (Waters, Milford, MA) cartridges 
to separate authentic FMZ from labeled metabolites as de- 
scribed previously 1201. The arterial blood was centrifuged 
and the plasma was applied to the column. A metabolite and 
an FMZ fraction were then obtained for each sample by 
prewashing the column with 9 ml of a 3 5 %  methanol/sodium 
phosphate buffer solution and 5 ml of loo%, methanol, re- 
spectively. The separation was corrected for loss of authentic 
FMZ with the metabolite fraction on the basis of ['HIFMZ 
added as internal standard to each sample prior to processing. 
The ratio of [ "CIFMZ to ["Clmetabolites was determined 
in the well counter and the recovery of ['H}FMZ was deter- 
mined by liquid scintillation spectrometry. The arterial input 
function was then corrected for the metabolite fraction. 
Reulzgnment of the Images 
Reconstructed images were realigned with the use of small 
molecular sieve beads as fiduciaries to correct for subject 
motion during and between scanning sessions One bead was 
placed on the forehead and one behind each ear, and they 
stayed tightly attached to the scalp during the entire scanning 
period Approximately 1 pl of the ligand preparation was 
pipetted onto each bead as follows 6 bCi ["C] per bead 
prior to a receptor study and 1 5 pCi {'*F] prior to an FDG 
study. Following reconstruction of the dynamic PET se- 
quence, each bead was marked with a cursor on the 7 5-  to 
10 0-minute frame and the (x, y, z) coordinates were calcu- 
lated based on the radioactivity distribution in the vicinity of 
the beads This frame defined the standard orientation An 
automated routine then located and calculated the (x, y, z) 
coordinates for each bead in the other 1 4  frames. These 
frames were then realigned to the orientation of the standard 
frame. With this method, it is possible to correct for the 
three translational and three rotational degrees of freedom 
Inplane (x and p) translation error is smaller than 0 1 plxel 
(approximately 0 15 mm), the axial translation error (2) is 
smaller than 0.1 plane (approxlmately 0 5 mm), and the rota- 
tion errors (xy, xz, yz) are smaller than 0.2 degree. Good 
realignment was achieved in all studies 
Compartmental Anabszs of {I1C}Flumuzenzl 
Trunsport and Distribution 
The dynarmc series of emission scans obtained from the re- 
ceptor studies was analyzed together with the metabolite- 
corrected arterial input curve on the basis of a two- 
compartment, two-parameter model. The model consists of 
an intravascular compartment and a single tissue compart- 
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ment accounting for the combined tracer activity of free, 
nonspecific, and specific binding pools. The estimated param- 
eters are the ligand transport from blood to brain, K, (millili- 
ter of plasma/milliliter of braidmin) and the clearance rate 
from tissue back to blood, k, (min-'). The ratio of these two 
Parameters provides an estimate of the ligand's distribution 
volume (DV) in the brain, which is assumed to represent 
predominantly specific HZR binding. As shown previously 
[?I], I)V is linearly related to BZR density (H, pmol-* 
min :). Parametric images of K, and 1)V were generdted for 
each study on a pixel-by-pixel basis using a weighted integral 
technique similar to that used for the cerebral blood flow 
studies. 
Data Am~~L'3;sis 
Regions of interest were determined on the K,  images ob- 
tained from the Fh4Z study and were directly superimposed 
on the corresponding images of the D V  maps and FDG 
scans. The regions inclutled the frontal cortex, the occipital 
curtex, thalamus, caudate, putamen, cerebellar cortex, and 
the pons. Values from structures identified in both hemi- 
spheres were averaged for each subject. 
Based on previously puhlishecl autoradiographic studies 
Cl5- 181 as well as PET measurements ofglucose metabolism 
(1-61, we were primarily interested in changes in the caudate 
nucleus, as well as the putamen and the thalamus. An a priori 
hypothesis predicted decreases in caudate arid putaminal D V  
and glucose metabolic rate. K,, which is largely proportional 
to regional cerebral blood flow, was expected to show similar 
changes as seen for regional glucose metabolism. Due to 
either conflicting results on changes in thalamic glucose me- 
tabolism in HD E2, 3, 5 ,  61 or lack of previous reports on 
alterations in thalamic BZR distribution, it was difficult to 
anticipate any changes for that region. Paired Student's t tests 
were applied for comparison of regional mean values for 
transport rate and distribution volume for FMZ in the patient 
and control groups. The change in the metabolic rate of the 
caudate and putamen in the 1 ID patients (expressed as the 
percentage of the mean of  the control patients) was compared 
to the change in the FMZ D V  in the same regions (also 
expressed as a percentage of the control means) by analysis 
of variance (ANOVA). 
Results 
The Table summarizes the regional values for radioli- 
gand transport (K,) and E3ZK DV obtained for the 
["C)FMZ studies in both patient and control groups. 
K: in both groups varied slightly from region to region 
and was highest in the thalamus, intermediate in the 
visual cortex and putamen, and lowest in the frontal 
cortex and posterior fossa. In HD, K, in the caudate 
was reduced by lT%,  (/.I = 0.02) when comparing pa- 
tient and control groups. Furthermore, K, values re- 
vealed a nonsignificant decrease in the putamen by g%, 
whereas in all other regions analyzed they were slightly 
increased. 
DV imilliliter of plasma/milliliter of tissue) varied 
about fivefold between regions (see Table). As previ- 
ously observed 1201, the highest receptor densities in 
patients and control subjects were found in the frontal 
and visual cortices, followed by the putamen, thalamus, 
and cerebellar cortex. The lowest d u e s  were demon- 
strated in the pons. Values of IIV were lower in pa- 
tients with H D  than in control subjects in all supraten- 
tond regions but the decrease reached significdnce 
only in the caudate ( 2 6 q  reduction, p = 0.02). 
The FDG scans were carried out in the same H D  
patients as were the FMZ scans but they were com- 
pared to a different group of 17 age-matched normal 
control sublects. Glucose metabolism in the HD group 
was significantly decreased in the caudate and putamen 
by 4 7 q  and 4 1 2 ,  respectively ( p  < O.OOOl),  and also 
in the thalamus by 18% ( p  - 0.001). The comparison 
of regional ratios for LCMRG revealed a reduction in 
caudate metabolic rate (47%) that was more substantial 
than the decrease in FMZ DV (265 f ;  F(1,10) 
17.272; p = 0 . 0 0 2 ~  
Discussion 
Assessment of BZK density in living humans is now 
possible through the use of radiolabeled ligands and 
dynamic PET {20-251. Central-type BZRs are closely 
related to GABA receptors, and both receptors exist 
on a family of Iigand-gated chloride channels. GABA 
is the most important inhibitory Iieurotransmitter in 
the brain and its inhibitory function is mediated by 
changes in the chloride conductance of the neuronal 
membrane. Benzodiazepines increase the frequency of 
chloride channel openings, while the duration of open- 
ing events and channel conductance are not altered ifor 
a review, see [26, 27)). 
1' 'C}Flurnazenil IS a nonsubtype selective, central- 
type BZR antagonist with a high relative proportion 
of specific, receptor-mediated retention in the brain 
122-247. It is devoid of significant intrinsic pharmaco- 
logical activity, but potently antagonizes the effects of 
benzodiazepines. As demonstrated recently, a two- 
compartment, two-parameter tracer kinetic model pro- 
vides precise estimations of the kinetic behavior of 
["C}FMZ in the human brain [20, 21, 251 and makes 
it possible to obtain pixel-by-pixel maps of radioligand 
transport (K,) and receptor density (DV). DV is con- 
sidered tu represent predominantly specific BZR bind- 
ing. Allosteric interactions between GABA and BZRs 
have been described (agonist binding to one receptor 
increases agonist binding to the other [2G)), but as an 
antagonist, FMZ in vitro binding has been shown to 
be unaffected by endogenous or added GABA or  bar- 
biturates [28, 291. 
The pathology in HD is profound in the caudate and 
putamen but not all striatal neurons die as a conse- 
quence of the inherited gene defect. As many as 90% 
of striatal neurons are projection neurons, contain 
GABA, and are medium spiny neurons 17, 141. 
GABAergic striatal output neurons appear to inhibit 
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Regional Means for {"C)Fbmazenil Transport Rate (K,) and Distribution Volume (DVi in the Bruin" 
Patients Control Subjects 
DV K, DV Regions K, 
Caudate 0.28 -+ 0.03h 1.62 * 0.14h 0.33 ? 0.04 2.19 ? 0.48 
3.04 % 0.51 Putamen 0.33 ? 0.03 2.87 t- 0.27 
Thalamus 0.41 t 0.03 2.71 ? 0.25 0.39 % 0.05 2.96 ? 0.41 
Frontal cortex 0.31 2 0.03 4.20 * 0.62 0.30 ? 0.02 4.57 r 0.75 
Visual cortex 0.36 t 0.06 4.99 ? 0.71 0.35 -t 0.05 5.74 t 1.04 
Pons 0.35 2 0.04 1.09 0.14 0.31 t 0.05 1.01 * 0.10 
0.36 ? 0.03 
Cerebellum 0.33 2 0.06 3.24 * 0.37 0.32 -+ 0.06 3.25 i 0.30 
~ 
aData are means 2 standard deviations, in milliliters of ~lasmdmilliliter of tissueimin. 
bp = 0.02 by rwo-railed Student's t test. 
GABAergic neurons in the globus pallidus and sub- 
stantia nigra, which in turn project to the thalamus 
and brainstem (for review, see [lo]) .  Somatostatin and 
acetylcholine interneurons are relatively spared and the 
brunt of the pathology falls on the GABAergic projec- 
tion neurons. A s  shown in postmortem autoradio- 
graphic studies in patients with HD, the consequences 
of the loss of these projection neurons are caudate and 
putamen atrophy and compensatory upregulation of 
GABA receptors and BZRs [ 161 in the neurons of the 
denervated projection zones. In advanced cases of HD 
(> 10 years' duration) GABA and BZR density are re- 
duced by approximately 44 and 5S9& respectively, in 
the caudate and putamen. GABA receptors are in- 
creased by about 106% and BZRs, by 72% in the 
lateral globus pallidus 1181. Although the exact cellular 
location of BZR measured autoradiographically is not 
known, this increase is believed to be an attempt of 
the deafferentated neurons to maintain homeostasis by 
increasing their functional response to a decreased syn- 
aptic input 1161. In early HD (stages I and 11) only two 
postmortem cases have been examined and in those 
BZR density was reduced significantly by 44% in the 
putamen and increased by 58% in the lateral globus 
pallidus 1163. 
This is the first study of BZRs in living individuals 
with HD. PET measurements of BZR density and glu- 
cose metabolism were made in 6 patients with early 
HD (stages I and 11) following injection of ["C)FMZ 
and Cl8F1FDG, respectively. We examined BZR DV 
in cortical as well as subcortical regions and our partic- 
ular interest was directed toward possible changes in 
the metabolic rate and BZR density in the caudate, 
putamen, and thalamus when comparing patients to 
healthy control subjects. The PET technique is excel- 
lent for measuring metabolic and neurochemical pa- 
rameters early in a disease process without confound- 
ing factors of drug effects or other illnesses. It would 
also have been of interest to examine pallidal BZRs in 
vivo and to verify the changes described in postmortem 
studies of advanced HD and also two brains with early 
HD rl5-181. One of the restrictions of the PET tech- 
nique for in vivo studies of basal ganglia, however, is 
that accurate measurements of globus pallidus activity 
are not possible due to its small volume, scanner reso- 
lution, and difficulty discriminating between putamen 
and pallidum in our PET images. The globus pallidus 
is threefold smaller than the putamen, and its volume 
is approximately 40% below that required for a struc- 
ture to be measured accurately with our scanner reso- 
lution [ l l ) .  
We found that radioligand transport (K,) and BZR 
DV in the patient group are significantly decreased 
only in the caudate nucleus and did not reach signifi- 
cance in the putamen and thalamus. Glucose metabo- 
lism, however, is significantly reduced in the caudate 
as well as in the putamen and thalamus. The present 
study reveals findings and results that corroborate 
some of the previously published observations in HD. 
The changes observed in BZR density and glucose me- 
tabolism in the caudate nucleus are commensurate with 
previously reported results of postmortem autoradio- 
graphic studies [ 15- 181 and with PET measurements 
of glucose metabolism [ 1-61, respectively. It has been 
described that in early stages of HD, as in the patients 
presented here, caudate metabolism is affected more 
dramatically than is putamen metabolism 137 and 
pathological findings reveal that the disorder begins in 
the caudate nucleus and then progresses to the puta- 
men Cl51. Although the patients studied here exhib- 
ited little or no cerebral atrophy as measured by cranial 
CT or MRI, it should be considered that the changes 
found for the caudate nucleus may arise either by loss 
of binding sites and decreased neuronal function or by 
atrophy and partial volume artifact. The latter, how- 
ever, is not supported by the fact that the change in 
K, is far smaller than the changes observed for DV 
and glucose metabolic rate. Changes reflecting merely 
cell loss would be expected to effect both transport 
rate and glucose metabolism to a similar degree. The 
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modest decrease in putaminal DV differs from post- 
mortem autoradiographic results that have described a 
pronounced decrease in BZR density. However, post- 
mortem data were found in patients with advanced 
HD, and only 2 with early HD have been studied so 
far C161. It could be that in early HD the typical de- 
crease in putaminal BZR density has not yet occurred. 
Walker and colleagues [ 161 reported that putaminal 
GABA and BZR levels in 2 patients with early HD 
(without obvious neuronal cell loss) were intermediate 
between those of control subjects and patients with 
advanced HD. The pallidal BZR DV was increased in 
these early cases almost to the level seen in advanced 
HD 1161. We also considered the possibility that our 
measured putamen values were artificially high because 
of partial volume averaging of the pallidum (which is 
expected to show increased receptor density) and in- 
sula that may be contributing activity to the putamen. 
We have performed simulation studies, however, that 
do not support this hypothesis. Computer-generated 
PET data sets were produced simulating the isotope 
distribution found in {"CJFMZ receptor scans using a 
computerized digital brain phantom as described previ- 
ously [321. 
Thalamic glucose metabolism is significantly re- 
duced, but measurements of K, and DV in the 
["C}FMZ scans show no significant change. Previous 
studies either have failed to show a significant change 
in thalamic metabolism 12, 5,6} or have demonstrated 
increased metabolism [3}. Metabolic impairment of the 
thalamus in HD could be the result of selective neu- 
ronal degeneration. Dom and colleagues {33} demon- 
strated a 50% decrease in the small-cell population of 
the ventrolateral group of the thalamus with a preserva- 
tion of the macroneuronal population. The small cells 
constitute 25 to 35% of the neuronal population in this 
region. Decreased thalamic BZR density was revealed 
previously in a postmortem autoradiographic study of 
advanced HD only El51 and in rats following striatal 
kainic acid lesions [34}. More advanced or severe stria- 
tal pathology may be necessary for the production of 
secondary thalamic receptor changes. 
The present study suggests that regional metabolic 
and GABA/BZR changes in subcortical structures of 
HD patients do not occur with the same time course. 
Impairment of neuronal metabolism seems to predate 
GABA/BZR changes in stage I and I1 patients. Cau- 
date glucose metabolism and BZR density are already 
severely impaired when other subcortical structures re- 
veal only minor abnormalities. It will be important to 
determine the relationship of BZR changes to cogni- 
tive and motoric symptoms in this progressive disease. 
Possibly, the decline in BZK density might provide 
a more accurate estimate of disease progression than 
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